Meizhou
Meizhou
Meizhou, Guangdong, China50 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07222800 | |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer | HER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-09-29 | NCT05132582 | |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2026-09-28 | NCT05100862 | |
| A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-09-24 | NCT07477587 | |
| An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2026-09-14 | NCT06589596 | |
| ASPIrin in Reducing Events in Dialysis ( ASPIRED ) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 4 | 2026-09-14 | NCT04381143 | |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-08-24 | NCT06970743 | |
| BDB-001 Phase III Trial in ANCA-Associated Vasculitis | Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, immune system disorder, necrotizing vasculitis, skin disorder, skin vascular disease, vascular disorder, vasculitis | Recruiting | Phase 3 | 2026-08-13 | NCT07168161 | |
| DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction | Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not stated | 2026-08-12 | NCT07761390 | |
| A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors | Advanced Solid Tumors | Active, not recruiting | Phase 1 | 2026-08-07 | NCT05502393 | |
| A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B | Blood-Borne Infections, Chronic Disease, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Hepadnaviridae infectious disease, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic hepatitis B virus infection, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Recruiting | Phase 2 | 2026-07-29 | NCT07635186 | |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-07-22 | NCT05253651 | |
| PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke | Arterial Occlusive Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Atherosclerotic, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, intracranial arterial disease, intracranial arteriosclerosis, nervous system disorder, vascular disorder | Not yet recruiting | Phase 4 | 2026-07-15 | NCT07466251 | |
| Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-13 | NCT07697443 | |
| Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors | MSI-H/dMMR Solid Tumors | Recruiting | Phase 2 | 2026-07-10 | NCT03736889 | |
| Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment | Aneurysm, abdominal aortic aneurysm, aortic aneurysm, aortic disorder, cardiovascular disorder, vascular disorder | Recruiting | Not stated | 2026-06-29 | NCT07674173 | |
| A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 3 | 2026-06-29 | NCT07673029 | |
| Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 3 | 2026-06-25 | NCT07385703 | |
| PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis | Arterial Occlusive Diseases, Intracranial Atherosclerosis, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Atherosclerotic, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, intracranial arterial disease, intracranial arteriosclerosis, nervous system disorder, vascular disorder | Recruiting | Phase 4 | 2026-06-12 | NCT06902740 | |
| A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-05-26 | NCT07375316 | |
| A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-05-22 | NCT07462143 | |
| Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | Moderately to Severely Active Ulcerative Colitis | Active, not recruiting | Phase 3 | 2026-05-22 | NCT03221036 | |
| A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 3 | 2026-05-14 | NCT05652894 | |
| Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy | Acute Ischemic Stroke, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 2 | 2026-05-12 | NCT07581210 | |
| A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 3 | 2026-03-27 | NCT07043725 |